Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bluejay Diagnostics (BJDX) Net Cash Flow (2022 - 2023)

Bluejay Diagnostics (BJDX) has disclosed Net Cash Flow for 2 consecutive years, with -$2.9 million as the latest value for Q4 2023.

  • Quarterly Net Cash Flow rose 9.87% to -$2.9 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$7.9 million through Dec 2023, up 11.57% year-over-year, with the annual reading at $862930.0 for FY2025, 58.78% down from the prior year.
  • Net Cash Flow hit -$2.9 million in Q4 2023 for Bluejay Diagnostics, down from -$23470.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of -$23470.0 in Q3 2023 to a low of -$3.3 million in Q1 2023.